Open AccessSustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia
Author(s) -
Caslin A. Gilroy,
Megan E. Capozzi,
Anastasia Kristine Varanko,
Jenny Tong,
David A. D’Alessio,
Jonathan E. Campbell,
Ashutosh Chilkoti
Publication year - 2020
Publication title -
science advances
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.928
H-Index - 146
ISSN - 2375-2548
DOI - 10.1126/sciadv.aaz9890
Subject(s) - fgf21 , agonist , glycemic , diabetes mellitus , liraglutide , type 2 diabetes , glucagon like peptide 1 , pharmacology , receptor , glucagon like peptide 1 receptor , medicine , insulin , endocrinology , chemistry , fibroblast growth factor
A type 2 diabetes therapeutic merges two complementary drugs with a depot-forming linker to enable once-weekly dosing.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom